CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation

2011 ◽  
Vol 33 (3) ◽  
pp. 290-298 ◽  
Author(s):  
J. WANG ◽  
W. LI ◽  
L. LI ◽  
X. YU ◽  
J. JIA ◽  
...  
2021 ◽  
Author(s):  
Weigang Sun ◽  
Lei Yang ◽  
Min Luo

Abstract In this paper, we propose a general acute myeloid leukaemia (AML) model and introduce an immune response and time delays into this model to investigate their effects on the dynamics. Based on the existence, stability and local bifurcation of three types of equilibria, we show that the immune response is a best strategy for the control of the AML on the condition that the rates of proliferation and differentiation of the hematopoietic lineage exceed a threshold. In particular, a powerful immune response leads to bi-stability of the steady states, and a stronger response wipes out all the leukaemia cells. In addition, we further reveal that the time delays existing in the feedback regulation and immune response process induce a series of oscillations around the steady state, which shows that the leukaemia cells can hardly be eliminated. Our work in this paper aims to investigate the complex dynamics of this AML model with the immune response and time delays on the basis of mathematical models and numerical simulations, which may provide a theoretical guidance for the treatments of the AML.


2019 ◽  
Vol 19 (4) ◽  
pp. 233-234
Author(s):  
Jorrit Schaefer ◽  
Sorcha Cassidy ◽  
Rachel M. Webster

2005 ◽  
Vol 44 (03) ◽  
pp. 107-117
Author(s):  
R. G. Meyer ◽  
W. Herr ◽  
A. Helisch ◽  
P. Bartenstein ◽  
I. Buchmann

SummaryThe prognosis of patients with acute myeloid leukaemia (AML) has improved considerably by introduction of aggressive consolidation chemotherapy and haematopoietic stem cell transplantation (SCT). Nevertheless, only 20-30% of patients with AML achieve long-term diseasefree survival after SCT. The most common cause of treatment failure is relapse. Additionally, mortality rates are significantly increased by therapy-related causes such as toxicity of chemotherapy and complications of SCT. Including radioimmunotherapies in the treatment of AML and myelodyplastic syndrome (MDS) allows for the achievement of a pronounced antileukaemic effect for the reduction of relapse rates on the one hand. On the other hand, no increase of acute toxicity and later complications should be induced. These effects are important for the primary reduction of tumour cells as well as for the myeloablative conditioning before SCT.This paper provides a systematic and critical review of the currently used radionuclides and immunoconjugates for the treatment of AML and MDS and summarizes the literature on primary tumour cell reductive radioimmunotherapies on the one hand and conditioning radioimmunotherapies before SCT on the other hand.


Sign in / Sign up

Export Citation Format

Share Document